These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22423020)

  • 1. Human papillomavirus vaccine and pregnancy.
    Narducci A; Einarson A; Bozzo P
    Can Fam Physician; 2012 Mar; 58(3):268-9. PubMed ID: 22423020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy.
    Forinash AB; Yancey AM; Pitlick JM; Myles TD
    Ann Pharmacother; 2011 Feb; 45(2):258-62. PubMed ID: 21285408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.
    Garland SM; Ault KA; Gall SA; Paavonen J; Sings HL; Ciprero KL; Saah A; Marino D; Ryan D; Radley D; Zhou H; Haupt RM; Garner EIO;
    Obstet Gynecol; 2009 Dec; 114(6):1179-1188. PubMed ID: 19935017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
    Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
    Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV vaccines and pregnancy.
    Prescrire Int; 2015 Oct; 24(164):239-40. PubMed ID: 26594728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine.
    Dana A; Buchanan KM; Goss MA; Seminack MM; Shields KE; Korn S; Cunningham ML; Haupt RM
    Obstet Gynecol; 2009 Dec; 114(6):1170-1178. PubMed ID: 19935016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
    Pomfret TC; Gagnon JM; Gilchrist AT
    J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV vaccines and pregnancy: the situation in early 2012.
    Prescrire Int; 2012 Jun; 21(128):154-7. PubMed ID: 22822594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on quadrivalent human papillomavirus vaccination and pregnancy outcomes: is contraception advisable?
    Obstet Gynecol; 2009 Dec; 114(6):1168-1169. PubMed ID: 19935015
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of human papillomavirus vaccines: a review.
    Stillo M; Carrillo Santisteve P; Lopalco PL
    Expert Opin Drug Saf; 2015 May; 14(5):697-712. PubMed ID: 25689872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
    Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
    Garnock-Jones KP; Giuliano AR
    Drugs; 2011 Mar; 71(5):591-602. PubMed ID: 21443282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults.
    Moreira ED; Palefsky JM; Giuliano AR; Goldstone S; Aranda C; Jessen H; Hillman RJ; Ferris D; Coutlee F; Vardas E; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Hum Vaccin; 2011 Jul; 7(7):768-75. PubMed ID: 21712645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA; Perry CM
    Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women.
    Perez G; Lazcano-Ponce E; Hernandez-Avila M; García PJ; Muñoz N; Villa LL; Bryan J; Taddeo FJ; Lu S; Esser MT; Vuocolo S; Sattler C; Barr E
    Int J Cancer; 2008 Mar; 122(6):1311-8. PubMed ID: 18000825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.
    Giacomet V; Penagini F; Trabattoni D; Viganò A; Rainone V; Bernazzani G; Bonardi CM; Clerici M; Bedogni G; Zuccotti GV
    Vaccine; 2014 Sep; 32(43):5657-61. PubMed ID: 25149430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.